Sangamo
Biogen and Sangamo work on Parkinson’s and Alzheimer’s gene therapies
Richard Staines
Alzheimer's, Biogen, gene therapy, neurology, Parkinson's, R&D, Sangamo
0 Comment
Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
Q&A: Sangamo’s Duncan McKay on genomic medicines
Oncology/ R&D/ Views & Analysis/ Views and analysis
Kite and Sangamo come together in $3bn cancer gene editing alliance
Andrew McConaghie
cell and gene therapy, gene editing, Gilead, Kite, Sangamo
0 Comment
No safety concerns so far in Sangamo’s groundbreaking gene-editing trial
Andrew McConaghie
advanced therapies, gene editing, gene therapy, Rare diseases, Sangamo
0 Comment
Sangamo and new gene therapy partner Pfizer lifted by FDA fast track
Andrew McConaghie
cell and gene therapy, gene therapy, haemophilia A, Pfizer, Sangamo
0 Comment